<DOC>
	<DOCNO>NCT01514240</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy D9421-C 9 mg daily compare Mesalazine 1 g three time day patient mild moderate active Crohn 's disease affect ileum , ileocecal region and/or ascend colon define score 180-400 Crohn 's Disease Activity Index ( CDAI ) assessment remission 8-week treatment define CDAI score ≤ 150 .</brief_summary>
	<brief_title>Phase III Study D9421-C 9 mg Patients With Active Crohn 's Disease Japan</brief_title>
	<detailed_description>A multicentre , double-blind , randomise , parallel-group , Phase III study ass efficacy safety D9421-C 9 mg versus Mesalazine 3 g patient active Crohn 's Disease ( CD ) Japan</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>15 year age old Main active disease ileal , ileocecal region , and/or ascend colon If treat partial nutrition treatment ( ≤1200 kcal/day ) treat azathioprine ( ≤2.0 mg/kg/day ) 6mercaptopurine ( ≤1.2 mg/kg/day ) , prior randomisation study completion discontinuation Ability read , write fill diary card HRQL questionnaire Having mild moderate active Crohn 's disease , define CDAI score 180400 baseline Patient CD lesion status may affect evaluation efficacy ( e.g . lesion upper GI , active anorectal lesion , abscess formation , stenosis , fistula , ostomy , short bowel uncontrolled concomitant disease ) Patient need concomitant treatment CD may affect assessment efficacy study drug Patient need medication prohibit due suspect influence metabolism study drug Patient judge inadequate participate study safety point view Patient wellfounded doubt protocol violation</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>mild moderate active Crohn 's disease</keyword>
	<keyword>affect ileum</keyword>
	<keyword>ileocecal region</keyword>
	<keyword>ascend colon</keyword>
	<keyword>score 180-400 CDAI</keyword>
</DOC>